A Stability-Indicating HPLC Method for Favipiravir and its Related Substances

Abstract

Background and Aims: This study aimed to improve an HPLC method for the quantification of favipiravir (FVP) and its impurities and apply it to a marketed pharmaceutical product. Methods: Chromatographic separations were achieved on a C18 column. The mobile phase comprised 10 mM potassium dihydrogen phosphate buffer (pH 4.0):acetonitrile (90:10 v/v) and acetonitrile in the gradient mode. The peaks were detected at 238 nm and the flow rate was set at 1.5 mL/min. The optimised method has been validated as per the International Conference on Harmonisation (ICH) guidelines Q2 (R1). A sharp peak of FVP was obtained at 5.5 min with no interfering peaks. In addition, the degradation study was conducted under acidic, basic, oxidative, photolytic, and thermal stress conditions. Results: In the calibration curve experiments, the linearity was between 0.5 – 3 μg/mL and r2=0.9985. Recovery ranging from 97.5% to 102.2% for the drug and impurities. The limit of detection (LOD) and limit of quantification (LOQ) concentrations of FVP and its impurities were 0.07 μg/mL and 0.2 μg/mL using s/ n:3, respectively. The precision studies were carried out and the relative standard deviation (RSD) values were found to be between 1.01 and 1.65% and 0.67-1.75% for intra-day precision and inter-day precision; respectively. No degradation peak appeared in the acidic hydrolysis, base hydrolysis, and photolysis stress studies. When the drug was subjected to thermal degradation, impurity B was observed. The degradation of the drug substances was obtained at 0.67% and 1.87% by thermal degradation and oxidation; respectively. Conclusion: The stability-indicating chromatographic methods for the determination of FVP and related components were developed and applied in tablets.

Keywords

• Favipiravir
• Pharmaceutical preparation
• Stability-indicating
• Validation

References

1. Agrahari, R., Mohanty S, Vishwakarma K, Nayak SK, Samantaray D., & Mohapatra S. (2021). Update vision on COVID-19: Structure, immune pathogenesis, treatment, and safety assessment. Sensors International, 2, 100073. doi: 10.1016/ j.sintl.2020.100073. google scholar
2. Agraval, U., Raju, R., & Udwadia, ZF. (2020). Favipiravir: A new and emerging antiviral option in COVID-19. Medical Journal, Armed Forces India, 76, 370-376. https:// doi.org/10.1016/j.mjafi.2020.08.004 google scholar
3. Babaei, F., Mirzababai, M., Nassiri-Asl, M., & Hosswinzadeh, H. (2021). Review of registered clinical trials for the treatment of COVID-19. Drug Development Research, 82, 474-493. https://doi.org/10.1002/ddr.21762 google scholar
4. Bulduk, I. (2020). HPLC-UV method for quantification of Favipiravir in pharmaceutical formulations. Acta Chromatographica, 33, 209-215. https://doi.org/10.1556/ 1326.2020.00828 google scholar
5. Guangling, F., Wenjuan, D., Yuxiao, D., Ren-Yang, Z., Yan, G., Chong-Gang, D., & Jinrui, S. (2015). HPLC method for mea-suring related substances in Favipi-ravir (Chinese Patent No CN104914185A). Shandong Academy of Pharmaceutical Sci-ences, https://patents.google.com/patent/CN104914185A/en google scholarGuangling, google scholar
6. F., Wenjuan, D., Yuxiao, D., Ren-Yang, Z., Yan, G., Chong-Gang, D., & Jinrui, S. (2016). A kind of Favipiravir has the HPLC assay method of related substance (Chinese Patent No. CN104914185B) Shandong Academy of Pharmaceutical Sci-ences, https://patents.google.com/patent/CN104914185B/en google scholar google scholar
7. Furuta, Y., Gowen, BB., Takahashi, K., & Shiraki, K. (2013). Favipiravir (T-705), A novel viral RNA polymerase inhibitor. Antiviral Research, 100, 446-454. https://doi. org/10.1016/j.antiviral.2013.09.015 google scholar
8. Gülşen, B., & Ertürk Toker, S. (2024). Development and validation of stability indicating HPLC method for favipiravir used in the treatment of the Covid-19 disease. İstanbul Journal of Pharmacy, 54(2), 223-232. https://doi.org/10.26650/ IstanbulJPharm.2024.1368223 google scholar

9. Sangani M.B. & Patel N., (2024). An Eco-Friendly RP-HPLC Method Development and Validation for Quantification of Favipiravir in Bulk and Tablet Dosage Form Followed by Forced Degradation Study. J Chromatogr Sci. 2024 May 31, 62(5), 432-438. doi: 10.1093/chromsci/bmad093. PMID: 38266038. google scholar
10. ICH Q2 . Guideline (2023). Analytical Validation. google scholar
11. Megahed, SM., Habib, AA., Hammad, SF., Kamal, AH. (2020). Experimental design approach for development of spectrofluorimetric method for determination of Favipiravir; a potential therapeutic agent against COVID-19 virus. Spectrochim-ica Acta, 249, 1-7. https://doi.org/10.1016/j.saa.2020.119241 google scholar
12. Toyama Chemicals. Summary of Product Characteristics of Avigan. google scholar
13. Favipiravir | C5H4FN3O2 | CID 492405 - PubChem google scholar
14. 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carbonitrile | C5H2FN3O | CID 22662785 - Pub-Chem google scholar
15. 6-Bromo-3-hydroxypyrazine-2-carboxamide | C5H4BrN3O2 | CID 9794418 - PubChem google scholar